Stay Up to Date on The Latest News Regarding Covid-19

​Wells Health Group is a Health Policy Consulting and Government Relations Firm Based in Washington D.C. 

WHG Helps Clients Navigate the New Federal Emergency Regulations & Beyond
WHG specializes in health policy consulting for life science companies to help maximize stakeholder value:
  • Biopharmaceutical 
  • Behavioral Health
  • Infectious disease
  • Medical device 
  • Specialty pharmacy
  • Medical management
  • Physician services
  • M&A advisors
Wells Health Group Areas of Expertise
Health Policy Consulting
Government Relations
M&A Consulting

COVID-19 Reality - New Federal Regulations - Post Outbreak & Beyond

  • New CMS reimbursement pathways in aggregate with the newly formed Technology Coding and Pricing Group to allow for faster access to innovative technologies.
  • New FDA Emergency Use Authorization (EUA) regulations to allow for unapproved medical products or unapproved uses of approved medical products to be used in an emergency.
  • New CDC public health guidance, evolving as the knowledge base grows, and expanded/refined data reporting.
  • New NIH infectious disease research and expanded medical and behavioral health research.

COVID-19 Reality - Impact on Budget Neutrality

  • COVID-19 Reality is playing a critical role in the 2021 annual HHS budgeting process and the subsequent Mandated Budget Neutral fee-for-service and prospective payment systems.
  • Health and Human Services (HHS) has 11 operating divisions, including eight agencies in the U.S. Public Health Service and three human services agencies.
  • HHS  outlays, as reported in the HHS 2021 total budget = $1.370 Trillion - Medicare = $728.2 Billion & Medicaid = $448.1 Billion
  • Budget Neutral Mandates to offset the increases in pandemic spending have resulted in various across-the-board  proposed 2021 payment schedule reductions; e.g. the Medicare Physicians Fee Schedule RVU Conversion Factor reduction is -10.6%.  Depending on the physician specialty the net decreases in fees could range from -5% to -12%.

Wells Health Group - Innovators in Health Policy & Government Relations

WHG's innovative approach to health policy consulting and government relations is built on a two-step sequential process founded on 70+ years successful healthcare industry and government relations experience:
  1. A core set of essential strategy analytics - deep dive into the client’s requirements and an analysis of supporting data to develop executable solutions
  2. Focused reimbursement pathways - evidence based and data driven
Post pandemic outbreak - Federal Agencies, Congress and the Administration require more and more decision-making to be made based upon clinical data evidence – the science supporting the decision.
​WHG's two-step process remains the successful foundation of our innovative approach to health policy consulting and government relations - clinical data evidence. Our proven processes helps us collaborate with clients to more effectively navigate all the new emergency use federal regulations.
WHG's two-step process remains the successful foundation of our innovative approach to health policy consulting and government relations - clinical data evidence. Our proven processes helps us collaborate with clients to more effectively navigate all the new emergency use federal regulations.

​​Why Our 70+ Years Industry & Government Relations Experience Matters

  • Because we come from the healthcare industry - WHG is uniquely positioned to best understand our client’s challenges and develop targeted government relations’ strategies.
  • Because of our government relations experience representing industry we knew it was critical for WHG to have a Washington D.C. presence.
  • Because WHG is strategically located on Pennsylvania Avenue between the Capitol and the White House and just six blocks for the main HHS building, WHG has been able to more readily access face-to-face meetings at multiple levels of the HHS Agencies and on Capitol Hill.
  • Because WHG's previous years of Washington D.C. presence with face-to-face meetings at multiple levels of  the HHS Agencies and on Capitol Hill, we are a known entity and know how to leverage  virtual access  to multiple levels of the HHS Agencies and on Capitol Hill.​​
CMS reimbursement processes, CDC guidance, FDA regulations and NIH expanded research
Federal Regulations are not intuitive and can lead to uncertainties and market access complications especially during the HHS Emergency Use Authorization (EUA) authority